Journey Medical Corporation (DERM)
NASDAQ: DERM · IEX Real-Time Price · USD
3.630
+0.120 (3.42%)
May 2, 2024, 4:00 PM EDT - Market closed
Journey Medical Revenue
In the year 2023, Journey Medical had annual revenue of $79.18M with 7.48% growth. Revenue in the quarter ending December 31, 2023 was $15.26M, a -4.44% decrease year-over-year.
Revenue (ttm)
$79.18M
Revenue Growth
+7.48%
P/S Ratio
0.92
Revenue / Employee
$1,931,244
Employees
41
Market Cap
72.50M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 79.18M | 5.51M | 7.48% |
Dec 31, 2022 | 73.67M | 10.54M | 16.69% |
Dec 31, 2021 | 63.13M | 18.60M | 41.78% |
Dec 31, 2020 | 44.53M | 9.61M | 27.52% |
Dec 31, 2019 | 34.92M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDERM News
- 1 day ago - Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer - GlobeNewsWire
- 7 days ago - Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation to Participate in the 36th Annual ROTH Conference - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting - GlobeNewsWire
- 4 months ago - Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea - GlobeNewsWire